Please assess the completion status of the following clinical trial:

Trial Title: Therapy of Chronic Cold Agglutinin Disease With Eculizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals at least 18 years of age~* Diagnosis of CAD defined by the combination of chronic hemolysis, cold agglutinin titer (IgM or IgA) \>64 at 4°C, positive direct antiglobulin test (DAT) when performed with polyspecific antiserum, negative (or only weakly positive) anti-IgG, and strongly positive with anti-C3d~* LDH level \> 2 x upper limit of normal (ULN)~* Clinical symptoms requiring treatment, such as anemia, anemia-related symptoms or hemolysis-related symptoms~* Sufficient supplementation of iron, folic acid and vitamin B12 prior to treatment phase~* Patient must be willing and able to give written informed consent;~* Patients must be vaccinated against N. meningitidis at least 14 days prior treatment~* Patient must avoid conception during the trial using a method that is most appropriate for their physical state and culture~Exclusion Criteria:~* Active aggressive lymphoma requiring therapy or an active non-lymphatic malignant disease other than basal cell carcinoma or CIS of the cervix~* Liver disease with elevated LDH~* Absolute neutrophil count \< 500/µL~* Presence or suspicion of active bacterial or viral infection, in the opinion of the Investigator, at treatment start or severe recurrent bacterial infections~* Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to screening period~* Pregnant, breast-feeding, or intending to conceive during the course of the study, including the Post-treatment Phase~* History of bone marrow/stem cell transplantation~* Inability to cooperate or any condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study~* Hypersensitivity to eculizumab, to murine proteins or to one of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).